Genetic Analysis: Direct issue has now been registered with the Norwegian Register of Business Enterprises
18 juni, 09:30
Genetic Analysis: Direct issue has now been registered with the Norwegian Register of Business Enterprises
OSLO, NORWAY - June 18, 2025: Microbiome DX company Genetic Analysis AS ("GA" or the "Company") hereby announces that the direct issue which was announced in a press release on the 05.05.2025 and approved by the Annual General Meeting on 19.05.2025 has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret).
The directed issue provided the Company with approximately NOK 12.8 million by issuance of 14 890 576 new shares, before issue costs. The direct issue has now been registered with the Norwegian Register of Business Enterprises.
After this, the Company's new registered share capital is NOK 38 564 308,20 divided into 64 273 847 shares, each with a nominal value of NOK 0.60.
The Subsequent issue is still in the process of final allocation, payment and registration.
About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in sales, operations, bioinformatics, molecular biology, and bioengineering.
For more general information: www.genetic-analysis.com
Stay updated on GA and sign up for more investor-related information: https://www.genetic-analysis.com/subscriptions/
Interested in reading more about GA's products? Please visit ga-map.com
For further information, please contact:
Tore Grøttum, Interim CFO
E-mail: tg@genetic-analysis.com
Ämnen i artikeln
Genetic Analysis: Direct issue has now been registered with the Norwegian Register of Business Enterprises
18 juni, 09:30
Genetic Analysis: Direct issue has now been registered with the Norwegian Register of Business Enterprises
OSLO, NORWAY - June 18, 2025: Microbiome DX company Genetic Analysis AS ("GA" or the "Company") hereby announces that the direct issue which was announced in a press release on the 05.05.2025 and approved by the Annual General Meeting on 19.05.2025 has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret).
The directed issue provided the Company with approximately NOK 12.8 million by issuance of 14 890 576 new shares, before issue costs. The direct issue has now been registered with the Norwegian Register of Business Enterprises.
After this, the Company's new registered share capital is NOK 38 564 308,20 divided into 64 273 847 shares, each with a nominal value of NOK 0.60.
The Subsequent issue is still in the process of final allocation, payment and registration.
About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in sales, operations, bioinformatics, molecular biology, and bioengineering.
For more general information: www.genetic-analysis.com
Stay updated on GA and sign up for more investor-related information: https://www.genetic-analysis.com/subscriptions/
Interested in reading more about GA's products? Please visit ga-map.com
For further information, please contact:
Tore Grøttum, Interim CFO
E-mail: tg@genetic-analysis.com
Ämnen i artikeln
Fondernas placeringar
Placeras aktieanalyser
-992x558.png&w=3840&q=75)
Aktieråd
-160x160.jpg&w=3840&q=75)
Fondernas placeringar
Placeras aktieanalyser
Aktieråd
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
